Experimental cancer drug LY3405105 fails to advance in early trial

NCT ID NCT03770494

Terminated Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested the safety of an oral drug called LY3405105 in 54 people with advanced solid tumors. The trial was divided into two parts to find the right dose and to see if the drug could shrink tumors. However, the study was terminated early, meaning the drug did not show enough promise or had too many side effects to continue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3405105 (oral drug)
What this could lead to: If it works, this could point toward a treatment for advanced solid tumors.
What could go wrong: This was an early phase 1 trial with only 54 participants, and it was terminated early. The drug may not be effective or safe enough to continue development.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial endometrioid adenocarcinoma epithelioid sarcoma neoplasm ovarian clear cell tumor ovarian endometrioid adenocarcinoma soft tissue sarcoma synovial sarcoma triple-negative breast carcinoma urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Columbia University Medical Center

New York, New York, 10032, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Gustave Roussy

Villejuif, 94805, France
Highlands Oncology Group

Fayetteville, Arkansas, 72703, United States
Hospital Madrid Norte Sanchinarro

Madrid, 28050, Spain
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Institut Bergonie

Bordeaux, 33076, France
Institut Curie

Paris, 75248, France
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
National Cheng-Kung Uni. Hosp.

Tainan, 704, Taiwan
National Taiwan University Hospital

Taipei, 10048, Taiwan
Princess Margaret Hospital

Toronto, Ontario, M5TY 2M9, Canada
Smilow Cancer Hospital at Yale-New Haven

New Haven, Connecticut, 06511, United States
Taichung Veterans General Hospital

Taichung, 40705, Taiwan
Taipei Veterans General Hospital

Taipei, 11217, Taiwan
University of Pennsylvania Hospital

Philadelphia, Pennsylvania, 19104, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.